byiShook Opinion
Aug 30, 2024 - 11:20
Alnylam stock tumbled Friday after the company's Pfizer-rivaling heart disease treatment lagged expectations in a lengthy study. The post Alnylam Plummets, Reversing 50% Gain This Year, As Pfizer Rival Lags Expectations appeared first on Investor's Business Daily.
Alnylam stock tumbled Friday after the company's Pfizer-rivaling heart disease treatment lagged expectations in a lengthy study.
The post Alnylam Plummets, Reversing 50% Gain This Year, As Pfizer Rival Lags Expectations appeared first on Investor's Business Daily.